Transuite's Q2 Reveals $8M Loss, Toxic Convertible Debt, and a 1B Share Authorization
TRSO has more than doubled off its 52-week low of $0.055 on light trading volume (0.3× avg).
Summary
Transuite's Q2 report shows an $8M loss, new toxic convertible debt with 60% conversion discounts, a 1B share authorization, and ineffective internal controls.
Key Events · Earnings and Guidance · TRSO
-
Toxic Convertible Debt Issued
On June 23, 2026, Transuite issued a $130,000 convertible note to CFI Capital with a conversion price at 60% of the lowest trading price over 20 days. The embedded derivative created a $586,191 liability and a $474,191 loss.
-
Three More Toxic Notes in July
Subsequent events disclose three additional convertible notes issued July 7-13, 2026 to Quick Capital, Jefferson Street Capital, and Lambda Ventures totaling $82,777.78, all with the same 60% conversion discount.
-
Authorized Shares Increased 13x
On April 14, 2026, authorized common shares increased from 75,000,000 to 1,000,000,000. Outstanding shares grew from 61.3M to 80.3M during H1 2026.
-
Massive Share Issuance
19,095,565 new shares were issued in six months for debt settlements, acquisitions, and consultant services, with 1,355,251 more shares payable.
Analysis · TRSO · Technology
The Q2 2026 report confirms Transuite remains in severe financial distress. While the $8.0 million six-month net loss is driven almost entirely by non-cash stock-based compensation, the real story is the financing. A $130,000 convertible note issued to CFI Capital carries a conversion price at 60% of the lowest trading price—a toxic structure that creates a $586,191 derivative liability and exposes shareholders to massive dilution. Three more identical notes totaling $82,778 were issued in July. Meanwhile, authorized shares ballooned from 75 million to 1 billion, and 19.1 million new shares were issued in just six months. Management also disclosed that disclosure controls are not effective. This is a company funding itself through deeply dilutive, predatory financing while burning cash.
At the time of this filing, TRSO was trading at $0.24 on OTC in the Technology sector, with a market capitalization of approximately $19.2M. The 52-week trading range was $0.05 to $5.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.